Drug reference
HIV-1 infection (initiated by a specialist) ▶BY MOUTH ▶Adult: 200/245 mg once daily Pre-exposure prophylaxis of HIV-1 infection (initiated by a specialist) ▶BY MOUTH ▶Adult: 200/245 mg once daily DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg emtricitabine/tenofovir disoproxil.
PDF page 711
Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (April 2017) that emtricitabine with tenofovir disoproxil (Truvada ®) is accepted for use within NHS Scotland in combination with safer sex practices for pre-exposure prophylaxis of sexually acquired HIV-1 infection in adults at high risk. All Wales Medicines Strategy Group (AWMSG) decisions The All Wales Medicines Strategy Group has advised (September 2017) that emtricitabine/tenofovir disoproxil (Truvada ®) is not recommended for use within NHS Wales in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV 1 infection in adults at high risk. The case for cost- effectiveness has not been proven. Subsequent to this AWMSG recommendation, Truvada ® has been made available in Wales and is being provided through NHS Wales from 17 July 2017 for up to three years for use as pre-exposure prophylaxis. During this time, eligible patients will receive Truvada ® and data will be collected to assess its effectiveness at preventing HIV and address some of the concerns of AWMSG in relation to cost-effectiveness.
PDF page 711
→Appendix 1: tenofovir disoproxil
PDF page 711
Manufacturer advises caution (increased risk of hepatic side-effects).
PDF page 711
▶When used for HIV-1 infection Manufacturer advises avoid in severe impairment. ▶When used for Pre-exposure prophylaxis of HIV-1 infection Manufacturer advises avoid if creatinine clearance less than 60 mL/minute. Dose adjustments ▶When used for HIV-1 infection Manufacturer advises use normal dose every 2 days in moderate impairment.
PDF page 711
Patients with swallowing difficulties may disperse tablet in half a glass of water, orange juice, or grape juice (but bitter taste).
PDF page 711
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Emtricitabine with tenofovir disoproxil (Non-proprietary) Emtricitabine 200 mg,Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg Emtricitabine 200mg / Tenofovir 245mg tablets | 30 tablet P £355.73 DT = £355.73 (Hospital only) | 30 tablet P £106.72–£355.73 DT = £355.73 Infection ▶Ictastan (Actavis UK Ltd) Emtricitabine 200 mg,Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg Ictastan 200mg/245mg tablets | 30 tablet P £355.72 DT = £355.73 ▶Truvada (Gilead Sciences International Ltd) Emtricitabine 200 mg,Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg Truvada 200mg/245mg tablets | 30 tablet P £355.73 DT = £355.73 eiiii F 683
PDF page 711
Patients or carers should be given advice on how to administer emtricitabine with tenofovir tablets. Missed doses If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
PDF page 711
200/245 mg once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 711
200/245 mg once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 711
